Burundi vs Least developed countries: Antiretroviral therapy coverage
Burundi
93.0%
in 2024
Least developed countries
82.5%
in 2024
Burundi rank
11th
Least developed countries rank
10th
Antiretroviral therapy coverage over time
- Burundi
- Least developed countries
How they compare
Burundi currently reports 93.0% against 82.5% in Least developed countries, a difference of 10.5%.
That makes Burundi's figure about 1.1 times Least developed countries's.
The two have swapped places 3 times across 25 shared years of data; in 2000 it was Least developed countries ahead.
Burundi ranks 11th and Least developed countries ranks 10th of 143 countries.
Burundi has averaged higher in every one of the 3 decades both report.
Head to head by decade
| Decade | Burundi | Least developed countries | Difference | Ahead |
|---|---|---|---|---|
| 2000s | 6.4% | 5.3% | 1.1% | Burundi |
| 2010s | 49.6% | 43.0% | 6.6% | Burundi |
| 2020s | 89.6% | 75.5% | 14.1% | Burundi |
Averages of every year both report within each decade.
Frequently asked questions
- Which has higher antiretroviral therapy coverage, Burundi or Least developed countries?
- Burundi, at 93.0% against 82.5% in Least developed countries as of 2024.
- What is the difference in antiretroviral therapy coverage between Burundi and Least developed countries?
- 10.5%, with Burundi ahead.
- How many years of comparable data are there for Burundi and Least developed countries?
- 25 years are reported by both, from 2000 to 2024.
- How do Burundi and Least developed countries rank globally for antiretroviral therapy coverage?
- Burundi ranks 11th and Least developed countries ranks 10th of 143 countries.
- Where does this data come from?
- UNAIDS estimates, Joint United Nations Programme on HIV/AIDS (UNAIDS), published as Antiretroviral therapy coverage (% of people living with HIV). Statizoid refreshes it automatically from the source and publishes the full history for both places.
Individual pages
About this data
Antiretroviral therapy coverage indicates the percentage of all people living with HIV who are receiving antiretroviral therapy.